Joe Markson is a Principal at Novo Holdings, with extensive experience in venture investments, having held positions as Senior Associate and Associate within the firm since June 2020. Markson serves as a Board Observer for Hummingbird Bioscience and Ray Therapeutics, and is a Director on the Board of Directors for Riva Therapeutics. Engagements with Reneo Pharmaceuticals and 10x Genomics highlight a robust involvement in strategic development and portfolio management within the biotech sector. Prior experience includes consulting roles at The Boston Consulting Group and twoXAR Pharmaceuticals, focusing on management strategy and R&D planning. Markson holds a PhD in Biophysics from Harvard University, an MPhil in Chemistry from the University of Cambridge, and an AB in Biochemical Sciences from Harvard University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices